品牌资讯网欢迎您~!

设为首页

当前位置:首页>文传商讯列表

FDA Authorizes Marketing of IQOS as a Modified Risk Tobacco Product

时间:2020年07月08日 17:33:50

NEW YORK--(BUSINESS WIRE)--Regulatory News:

The U.S. Food and Drug Administration (FDA) today authorized the marketing of IQOS, Philip Morris International’s (PMI) electrically heated tobacco system, as a modified risk tobacco product (MRTP). In doing so, the agency found that an IQOS exposure modification order is appropriate to promote the public health.

- Today’s decision demonstrates that IQOS is a fundamentally different tobacco product and a better choice for adults who would otherwise continue smoking

IQOS is the first and only electronic nicotine product to be granted marketing orders through the FDA’s MRTP process

- The FDA authorized the marketing of IQOS with the following information:

- The IQOS System heats tobacco but does not burn it

- This significantly reduces the production of harmful and potentially harmful chemicals

- Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system reduces your body’s exposure to harmful or potentially harmful chemicals.

- The agency concluded that the available scientific evidence demonstrates that IQOS is expected to benefit the health of the population as a whole, taking into account both users of tobacco products and persons who do not currently use tobacco products

- The FDA’s decision further builds on the emerging independent international scientific consensus that IQOS is a better choice than continuing to smoke, and follows the FDA’s April 2019 decision authorizing the commercialization of IQOS in the U.S.

- The FDA’s decision provides an important example of how governments and public health organizations can regulate smoke-free alternatives to differentiate them from cigarettes in order to protect and promote the public health

This decision follows a review of the extensive scientific evidence package PMI submitted to the FDA in December 2016 to support its MRTP applications.

Commenting on the FDA’s announcement, André Calantzopoulos, PMI’s Chief Executive Officer, said:

“The FDA’s decision is a historic public health milestone. Many of the tens of millions of American men and women who smoke today will quit—but many won’t. Today’s decision makes it possible to inform these adults that switching completely to IQOS is a better choice than continuing to smoke. FDA determined that scientific studies show that switching completely from conventional cigarettes to IQOS reduces exposure to harmful or potentially harmful chemicals.

IQOS is a fundamentally different product than combustible cigarettes and must be regulated differently, as the FDA has recognized. Now—more than ever—there is an urgent need for a fundamentally different conversation on a cooperative approach to achieve a smoke-free future. The FDA’s decision provides an important example of how governments and public health organizations can regulate smoke-free alternatives to differentiate them from cigarettes in order to promote the public health.

We are excited that this important decision will help guide the choices of adult smokers in the U.S. The best choice for health is to never start smoking or to quit altogether. For those who don’t quit, the best thing they can do is switch to a scientifically substantiated smoke-free product. As of March 31, 2020, PMI estimates that approximately 10.6 million adult smokers around the world have already stopped smoking and switched to IQOS. We believe that this decision can help to further accelerate the transition of U.S. adults away from cigarettes. We, along with our licensee Altria, are committed to guarding against unintended use and fully support FDA’s focus on protecting youth.

Today’s decision is a result of our ongoing commitment to put science at the forefront as we continue on our quest to replace cigarettes with smoke-free alternatives as quickly as possible.

We look forward to working with the FDA to provide any additional information they may require in order to market IQOS with reduced risk claims.

Harnessing innovations like IQOS to dramatically speed-up the decline in cigarette smoking is the opportunity of this century. Comprehensive, science-based regulation can help to rapidly shift adult smokers who would otherwise continue smoking to better options, while simultaneously guarding against unintended consequences.”

Note to Editor

The MRTP marketing orders were issued pursuant to a 2009 law that empowers FDA to regulate tobacco products, including through oversight of innovative tobacco products.

PMI submitted MRTP applications for the IQOS device and three HeatStick variants: Marlboro HeatSticksMarlboro Smooth Menthol HeatSticks, and Marlboro Fresh Menthol HeatSticks.

On April 30, 2019, the FDA authorized IQOS for sale in the U.S. through issuance of premarket tobacco authorization marketing orders that deemed the marketing of the product appropriate for the protection of public health.

On March 30, 2020, PMI submitted a supplemental premarket tobacco product application for the IQOS 3 tobacco heating device with the FDA.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the U.S. under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2020, PMI estimates that approximately 10.6 million adult smokers around the world have already stopped smoking and switched to PMI's heat-not-burn product, available for sale in 53 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.

来源:  作者:
相关新闻
凤凰网友:memory’流年
评论:梦想是用来破灭的,不是用来实现的,因为在现实面前,它就是一个屁。

天涯网友:时光° Moon
评论:爱由一个笑容开始,用一个吻来成长,用一滴眼泪来结束。

腾讯网友:Curtain ( 落幕 )
评论:人生没有彩排,每天都是直播;不仅收视率低,而且工资不高。

百度网友:-旧流年 seven ||
评论:生活之所以有回忆,不是因为突然想起,而是因为不能忘记!

天猫网友:一个2B的男人
评论:活在自己的心里,不要活在别人的眼里。

猫扑网友:没感觉  End.ゝ
评论:每次听到有人在吆喝回收废品我就想到把你卖了。

其它网友:Sunny°刺眼
评论:长大成人这件事最恐怖的地方之一,在于,你或许会变成自己曾经最看不起的那种人。

网易网友:冷笑你的无知
评论:出门顶个避雷针,从此装B再也不怕遭雷劈!

淘宝网友:染尘 /9 Demon。
评论:我横溢的不只是才华而已,其实还有腰间的脂肪。

搜狐网友:Cool| 卡其布
评论:学习要加,骄傲要减,机会要乘,懒惰要除。

网站介绍 | 广告刊例 | 联系我们 | 版权声明 | 网站导航

品牌资讯网版权所有 未经允许 请勿复制或镜像 Copyright © 2012-2017 http://news.ppzixunw.com/, All rights reserved.